The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

  1. Rodríguez, P.C.
  2. Prada, D.M.
  3. Moreno, E.
  4. Aira, L.E.
  5. Molinero, C.
  6. López, A.M.
  7. Gómez, J.A.
  8. Hernández, I.M.
  9. Martínez, J.P.
  10. Reyes, Y.
  11. Milera, J.M.
  12. Hernández, M.V.
  13. Torres, R.
  14. Avila, Y.
  15. Barrese, Y.
  16. Viada, C.
  17. Montero, E.
  18. Hernández, P.
Aldizkaria:
Clinical and Experimental Immunology

ISSN: 1365-2249,  0009-9104

Argitalpen urtea: 2018

Alea: 191

Zenbakia: 2

Orrialdeak: 229-239

Mota: Artikulua

DOI: 10.1111/CEI.13061 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus